| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5642556 | Oral Oncology | 2017 | 8 Pages |
Abstract
Clinical benefit and overall survival from the dasatinib-cetuximab combination were improved among patients with low serum IL6. Preclinical studies support IL6 as a modifier of dasatinib-cetuximab response. In the setting of clinical cetuximab resistance, serum IL6 is a candidate predictive marker specific for combined dasatinib-cetuximab. The trial was modified and redesigned as a biomarker-enriched Phase II study enrolling patients with undetectable IL6.
Keywords
HNSCCHGFORRISHIRBSFKIL6EGFRIn situ hybridizationSrc-family kinasesPFsinterleukin-6progression-free survivaloverall survivalprogressive diseaseDasatinibCetuximabHepatocyte growth factorAdverse eventsVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)overall response rateinstitutional review boardHuman papilloma virusHPVHead and neck squamous cell carcinomaSrc-family kinaseEpidermal growth factor receptor
Related Topics
Health Sciences
Medicine and Dentistry
Dentistry, Oral Surgery and Medicine
Authors
L.P. Stabile, A.M. Egloff, M.K. Gibson, W.E. Gooding, J. Ohr, P. Zhou, N.J. Rothenberger, L. Wang, J.L. Geiger, J.T. Flaherty, J.R. Grandis, J.E. Bauman,